3rd Quarter - Report

EXPRESS SCRIPTS, INC. for EXPRESS SCRIPTS, INC.

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$500,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report (this page) Oct 16, 2014 $500,000 Replaced
3rd Quarter - Amendment Nov 11, 2014 $500,000 Yes

What was lobbied

7 issue areas, each in the filer's own words, with who lobbied on it and where.

Defense DEF

Pharmacy issues related to Section 700 (Champus provisions) of the annual defense bill

LobbyistCovered position, as disclosed
NANCY GILBRIDE —
GARY J KLINE Office of Congressman Brian Bilbray
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Medicare Payment Advisory Commission (MedPAC); Government Accountability Office (GAO); Centers For Medicare and Medicaid Services (CMS); Internal Revenue Service (IRS); Office of Personnel Management (OPM); Executive Office of the President (EOP); Labor, Dept of (DOL); Congressional Budget Office (CBO); SENATE; Federal Trade Commission (FTC); Health Resources & Services Administration (HRSA); Food & Drug Administration (FDA); White House Office; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Taxation/Internal Revenue Code TAX

Regulatory implementation of various tax provisions in the health reform legislation

LobbyistCovered position, as disclosed
GARY J KLINE Office of Congressman Brian Bilbray
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Labor, Dept of (DOL); Health Resources & Services Administration (HRSA); White House Office; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Congressional Budget Office (CBO); Government Accountability Office (GAO); Medicare Payment Advisory Commission (MedPAC); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Federal Trade Commission (FTC); Office of Personnel Management (OPM); SENATE; Internal Revenue Service (IRS); HOUSE OF REPRESENTATIVES

Postal POS

Postal Reform proposals and their impact on 6 day mail delivery

LobbyistCovered position, as disclosed
MARY M ROSADO —

Contacted: Health Resources & Services Administration (HRSA); Health & Human Services, Dept of (HHS); Food & Drug Administration (FDA); Office of Personnel Management (OPM); HOUSE OF REPRESENTATIVES; Internal Revenue Service (IRS); Federal Trade Commission (FTC); White House Office; Centers For Medicare and Medicaid Services (CMS); SENATE; Government Accountability Office (GAO); Labor, Dept of (DOL); Medicare Payment Advisory Commission (MedPAC); Congressional Budget Office (CBO); Executive Office of the President (EOP)

Labor Issues/Antitrust/Workplace LBR

Legislation to exempt certain pharmacies from the antitrust laws for purposes of negotiating with payers (HR 1188)

LobbyistCovered position, as disclosed
GARY J KLINE Office of Congressman Brian Bilbray
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Medicare Payment Advisory Commission (MedPAC); HOUSE OF REPRESENTATIVES; Office of Personnel Management (OPM); Internal Revenue Service (IRS); Federal Trade Commission (FTC); Labor, Dept of (DOL); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Congressional Budget Office (CBO); Health Resources & Services Administration (HRSA); White House Office; Government Accountability Office (GAO); Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); SENATE

Bills named: H.R. 1188 (113th)

Medicare/Medicaid MMM

Health reform proposals that impact Medicare Part D such as formulary requirements, PBM disclosure provisions, closing of the Part D coverage gap. General reg/leg Part D issues such as direct negotiation (budget proposals). Statutory implementation of changes to the definition of AMP in Medicaid. Exclusion of specialty distributors' prompt pay discounts from the definition of Average Sales Price. Medicare audit and preferred network restrictions. S. 867, Medicare Prescription Drug Integrity andAnd Transparency Act of 2013 and other versions (HR 4437, S. 867, HR 4577. General issues and legislation (HR 3392) regarding combatting Rx abuse in Medicare and Medicaid (pharmacy lock-in, etc)

LobbyistCovered position, as disclosed
GARY J KLINE Office of Congressman Brian Bilbray
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Medicare Payment Advisory Commission (MedPAC); Food & Drug Administration (FDA); SENATE; Executive Office of the President (EOP); Office of Personnel Management (OPM); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); White House Office; Health Resources & Services Administration (HRSA); Internal Revenue Service (IRS); HOUSE OF REPRESENTATIVES; Labor, Dept of (DOL); Congressional Budget Office (CBO); Government Accountability Office (GAO); Federal Trade Commission (FTC)

Bills named: S. 867 (113th), H.R. 4437 (113th), H.R. 3392 (113th), H.R. 4577 (113th)

Pharmacy PHA

Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 1367); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); specialty pharmacy tiering restrictions (HR 460); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; policies placing restrictions on pharmacy benefit designissues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). General issues dealing with prescription drug abuse (HR 3392) including Medicare Lock-in programs. General issues dealing with regulating pharmacy drug compounding (PDSQ Act); S. 867 (and versions HR 4437, HR 4577), the Medicare Prescription Drug Program Integrity and Transparency Act.

LobbyistCovered position, as disclosed
NANCY GILBRIDE —
GARY J KLINE Office of Congressman Brian Bilbray
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Medicare Payment Advisory Commission (MedPAC); Office of Personnel Management (OPM); HOUSE OF REPRESENTATIVES; Internal Revenue Service (IRS); Congressional Budget Office (CBO); Federal Trade Commission (FTC); White House Office; Health & Human Services, Dept of (HHS); Government Accountability Office (GAO); Executive Office of the President (EOP); Health Resources & Services Administration (HRSA); SENATE; Food & Drug Administration (FDA); Centers For Medicare and Medicaid Services (CMS); Labor, Dept of (DOL)

Bills named: H.R. 4577 (113th), S. 867 (113th), H.R. 3392 (113th), H.R. 460 (113th), H.R. 4437 (113th), H.R. 1367 (113th)

Health Issues HCR

Regulatory policies related to health reform legislation: structure, drug benefits, disclosure Regulatory implementation of HITECH/Accounting of Disclosures Issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs). Restrictions on specialty tiering; HR 460

LobbyistCovered position, as disclosed
GARY J KLINE Office of Congressman Brian Bilbray
MARY M ROSADO —
SERGIO SANTIVIAGO —

Contacted: Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Medicare Payment Advisory Commission (MedPAC); SENATE; Congressional Budget Office (CBO); Federal Trade Commission (FTC); Executive Office of the President (EOP); Government Accountability Office (GAO); Health Resources & Services Administration (HRSA); White House Office; Centers For Medicare and Medicaid Services (CMS); Office of Personnel Management (OPM); Internal Revenue Service (IRS); Health & Human Services, Dept of (HHS); Labor, Dept of (DOL)

Bills named: H.R. 460 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.